Neuronetics, Inc. is the world's leader in advancing therapeutic applications of high field pulsed magnetics
for disorders of the central nervous system ( TMS Transcranial Magnetic Stimulation ). Neuronetics was founded
within The Innovation Factory, an Atlanta, GA based medical technology incubator in July of 2001. In April 2003,
the company raised $10MM in venture capital on the strength of its unique intellectual property portfolio and
experienced management team. Neuronetics is putting this capital to work fueling product development and conducting
a multi-center pivotal trial using its non-invasive technology in the treatment of major depression.
Transcranial Magnetic Stimulation, rTMS, TMS, Depression treatments, Depression, Depression clinical research,
Depression clinical trials, Depression research trials, Neuronetics, ECT, Electroconvulsive therapy, VNS, Vagus
nerve stimulation, Investors, Bruce Shook, President & CEO, Mark Bausinger, Mark Demitrack, MD, Chief Medical
Officer, Mark Riehl, VP Product Development & Operations, Stanford Miller, VP Business Development, Judy Ways,
Ph.D., VP RA/QA, resistent depression